See the DrugPatentWatch profile for lurbinectedin

Based on the information provided, there is no definitive answer regarding a delay in the therapeutic response of lurbinectedin. Lurbinectedin is a novel anticancer drug that has shown promising results in the treatment of certain types of cancer, such as small cell lung cancer and ovarian cancer [1]. However, the timeline and characteristics of its therapeutic response have not been extensively studied or documented.

It is important to note that the therapeutic response to any drug can vary significantly between individuals, depending on factors such as the type and stage of the cancer, the patient's overall health, and the dosage and administration of the drug. Therefore, it is not uncommon for there to be a delay in the therapeutic response to a new drug like lurbinectedin.

To better understand the therapeutic response of lurbinectedin, it would be helpful to consult clinical trials and studies that have investigated its use in cancer treatment. For example, a phase II clinical trial of lurbinectedin in patients with relapsed small cell lung cancer found that the drug showed clinical activity, with a median overall survival of 9.3 months [2]. However, this study did not specifically address the question of a delay in the therapeutic response.

In conclusion, while lurbinectedin has shown promise as a cancer treatment, there is currently no definitive information available regarding a delay in its therapeutic response. Further research and clinical trials are needed to better understand the characteristics and timeline of the drug's therapeutic response.

Sources:

1. DrugPatentWatch.com. (n.d.). Lurbinectedin. Retrieved from <https://www.drugpatentwatch.com/drugs/lurbinectedin>
2. Trigo, J., Subramaniam, S., Giaccone, G., Le Teuff, G., Popat, S., Felip, E., ... & von Pawel, J. (2020). Lurbinectedin in patients with relapsed small-cell lung cancer: a phase 2, open-label, single-arm trial. The Lancet Oncology, 21(5), 664-674.